Business Description
Cutia Therapeutics
ISIN : KYG2606C1006
Total Employee Number:
304Compare
Compare
Traded in other countries / regions
02487.Hong Kong Index Membership
Hong Kong Stock Connect IPO Date
2023-06-12Description
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.48 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -1.11 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.72 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 198.9 | |||||
3-Year EBITDA Growth Rate | 21.3 | |||||
3-Year EPS without NRI Growth Rate | 20.5 | |||||
3-Year FCF Growth Rate | 9.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 57.58 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.15 | |||||
9-Day RSI | 26.59 | |||||
14-Day RSI | 27.54 | |||||
3-1 Month Momentum % | -35.16 | |||||
6-1 Month Momentum % | -35.56 | |||||
12-1 Month Momentum % | -69.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.87 | |||||
Quick Ratio | 3.73 | |||||
Cash Ratio | 2.92 | |||||
Days Inventory | 147.93 | |||||
Days Sales Outstanding | 111.73 | |||||
Days Payable | 25.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.1 | |||||
Shareholder Yield % | -30.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.27 | |||||
Operating Margin % | -86.05 | |||||
Net Margin % | -100.66 | |||||
EBITDA Margin % | -84.92 | |||||
FCF Margin % | -89.75 | |||||
OCF Margin % | -85.94 | |||||
ROE % | -39.33 | |||||
ROA % | -26.96 | |||||
ROIC % | -56.57 | |||||
3-Year ROIIC % | 11.86 | |||||
ROC (Joel Greenblatt) % | -99.37 | |||||
ROCE % | -33.72 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.25 | |||||
PB Ratio | 0.91 | |||||
Price-to-Tangible-Book | 0.92 | |||||
EV-to-EBIT | -0.97 | |||||
EV-to-EBITDA | -1.11 | |||||
EV-to-Revenue | 0.95 | |||||
EV-to-Forward-Revenue | 41.45 | |||||
EV-to-FCF | -1.05 | |||||
Price-to-GF-Value | 0.15 | |||||
| Price-to-Net-Current-Asset-Value | 1.3 | |||||
| Price-to-Net-Cash | 2.2 | |||||
Earnings Yield (Greenblatt) % | -103.09 | |||||
FCF Yield % | -37.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cutia Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 370.582 | ||
| EPS (TTM) (HK$) | -1.129 | ||
| Beta | 1.355 | ||
| 3-Year Sharpe Ratio | -0.47 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 57.92 | ||
| 14-Day RSI | 27.54 | ||
| 14-Day ATR (HK$) | 0.199441 | ||
| 20-Day SMA (HK$) | 2.7615 | ||
| 12-1 Month Momentum % | -69.92 | ||
| 52-Week Range (HK$) | 2.37 - 12 | ||
| Shares Outstanding (Mil) | 363.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cutia Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cutia Therapeutics Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cutia Therapeutics Frequently Asked Questions
What is Cutia Therapeutics(HKSE:02487)'s stock price today?
The current price of HKSE:02487 is HK$2.46. The 52 week high of HKSE:02487 is HK$12.00 and 52 week low is HK$2.37.
When is next earnings date of Cutia Therapeutics(HKSE:02487)?
The next earnings date of Cutia Therapeutics(HKSE:02487) is .
Does Cutia Therapeutics(HKSE:02487) pay dividends? If so, how much?
Cutia Therapeutics(HKSE:02487) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cutia Therapeutics
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers